P. Bahri

发表

The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting standards

Meredith Y. Smith, P. Bahri, J. Gaudino, 2021, International journal of epidemiology.

Communicating about Risks and Safe Use of Medicines: Real Life and Applied Research

P. Bahri, 2020 .

A Multilayered Research Framework for Humanities and Epidemiology of Medicinal Product Risk Communication

P. Bahri, 2020 .

CIOMS Guide To Vaccine Safety Communication - Executive summary.

P. Bahri, L. Rägo, 2019, Vaccine.

Listen to the public and fulfil their information interests – translating vaccine communication research findings into guidance for regulators

P. Bahri, Mireia Castillon Melero, 2018, British journal of clinical pharmacology.

‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework

P. Bahri, Patrick Brown, 2019, European Journal of Clinical Pharmacology.

Pharmacovigilance‐related topics at the level of the International Conference on Harmonisation (ICH)

P. Bahri, P. Tsintis, 2005, Pharmacoepidemiology and drug safety.

The utility of real‐world evidence for benefit‐risk assessment, communication, and evaluation of pharmaceuticals: Case studies

K. Hornbuckle, Meredith Y. Smith, P. Bahri, 2020, Pharmacoepidemiology and drug safety.

Benefit–Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist

P. Mol, K. Hornbuckle, Meredith Y. Smith, 2015, Pharmacoepidemiology and drug safety.

Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects.

J. Avorn, A. Porsius, A. de Boer, 2000, Journal of clinical epidemiology.

How to improve communication for the safe use of medicines?: Discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug Monitoring.

P. Bahri, M. Harrison‐Woolrych, 2012, Drug safety.

Focusing on risk communication about medicines: why now?

P. Bahri, M. Harrison‐Woolrych, 2012, Drug safety.

Focusing on Risk Communication About Medicines

P. Bahri, M. Harrison‐Woolrych, 2012, Drug Safety.

The concept of vaccination failure.

P. Bahri, A. Dodoo, U. Heininger, 2012, Vaccine.

Authors’ Reply to Ravi Jandhyala’s Comment on “Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments”

P. Mol, P. McGettigan, P. Bahri, 2019, Drug Safety.

Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines

P. Bahri, D. Morales, X. Kurz, 2017, BMC Medicine.

Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines.

S. de Lusignan, M. Sturkenboom, H. Larson, 2019, Vaccine.

‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework

P. Bahri, Patrick Brown, 2019, European Journal of Clinical Pharmacology.

Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)

J. Dogné, P. Bahri, S. Straus, 2020, Drug Safety.

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

P. Mol, D. Postmus, P. Bahri, 2023, Drug Safety.

Regulatory Pharmacovigilance in the European Union

P. Bahri, P. Arlett, 2014 .

Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum

M. Lindquist, A. Bate, I. Edwards, 2014, Drug Safety.

Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States

M. D. De Bruin, J. Lexchin, P. Bahri, 2020, Clinical pharmacology and therapeutics.

The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products

P. Mol, Meredith Y. Smith, P. Bahri, 2017, Drug Safety.

The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance

I. Edwards, P. Mol, P. Bahri, 2015, Drug Safety.

Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.

Xavier Kurz, Peter G. M. Mol, P. Mol, 2019 .

How do safety warnings on medicines affect prescribing?

C. Dormuth, P. Bahri, B. Mintzes, 2022, Expert opinion on drug safety.

Public Pharmacovigilance Communication

P. Bahri, 2010, Drug safety.

Patient Registries: An Underused Resource for Medicines Evaluation

Xavier Kurz, Peter G. M. Mol, P. Mol, 2019, Drug Safety.

Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance

W. Gaissmaier, J. Aronson, G. Trifirò, 2023, Drug Safety.

Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse

A. Pariente, P. Bahri, 2021, Drug Safety.

An Update on ISoP Special Interest Groups (SIGs)

P. Bahri, J. Delumeau, Brian D Edwards, 2017, Drug Safety.

Regulatory Pharmacovigilance in the EU

P. Waller, P. Bahri, Priya Bahri, 2002 .

Communication in Drug Safety

I. Edwards, P. Mol, P. Bahri, 2011, Drug Safety.

How to Improve Communication for the Safe Use of Medicines?

P. Bahri, M. Harrison‐Woolrych, 2012, Drug Safety.

Pharmacovigilance‐related topics at the level of the International Conference on Harmonisation (ICH)

P. Bahri, P. Tsintis, 2005, Pharmacoepidemiology and drug safety.

The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System

P. Bahri, P. Arlett, Viola Macolić Šarinić, 2024, Drug safety.